Our young researchers under Janis Veliks supervision have published a case study which showed that fluorocyclopropane analogue of the anticancer drug cabozantinib shows improved selectivity against cancerous cells. Read the full article in the ACS Medicinal Chemistry Letters (IF=3.750, 2019):
Veliks, J.; Videja, M.; Kinens, A.; Bobrovs, R.; Priede, M.; Kuka J.
trans-Fluorine Effect in Cyclopropane: Diastereoselective Synthesis of Fluorocyclopropyl Cabozantinib Analogs.
ACS Med. Chem. Lett., 2020, DOI: 10.1021/acsmedchemlett.0c00220
These studies were financially supported by ERDF project Nr.1.1.1.5/17/A/003.